Action 4. Identification of new combined immunotherapies adapted to tumor biology

Partner responsible: PALOBIOFARMA SL

Partners involved: the entire consortium

In recent years there has been a breakthrough in the development of cancer treatments “chemotherapy-free”. In this context, immunotherapy is a type of cancer treatment designed to stimulate the patient’s immune system in a way that recognizes and combats the tumor. Among the most developed types of immunotherapies are monoclonal antibodies, which are drugs designed to bind specifically to key cells of the immune system or the tumor itself. In this sense, antibodies against CTLA-4 or PD-1 allow neutralizing these inhibitor molecules and triggering the immune response against the tumor. However, the tumor has developed other strategies to regulate negatively the anti-tumor response, highlighting the generation of the adenosine metabolite, with great immunosuppressive activity, which is presented at high concentrations in the tumor microenvironment. For this reason the new tendencies in immunotherapy propose combined therapies. These new targets are beginning to be explored with great success in cancers of solid tumors, but their potential in hematological cancers is still to be explored and confirmed.

IMLINFO has the following activities planned:

  • Synthesis of adenosine receptor inhibitors.
  • Study of effectiveness and mechanism of action.
  • Proof-of-concept trial in patients with NHL.
Scroll to top

This website uses its own operational cookies that have only a functional purpose and third-party cookies (analytics type) that allow you to know your browsing habits in order to provide you with better information services. If you continue browsing, you accept its use. You can change the settings, deactivate them or get more information. more information

Los ajustes de cookies de esta web están configurados para "permitir cookies" y así ofrecerte la mejor experiencia de navegación posible. Si sigues utilizando esta web sin cambiar tus ajustes de cookies o haces clic en "Aceptar" estarás dando tu consentimiento a esto.